ICU Medical (ICUI) to Release Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $1.91 per share and revenue of $533.3850 million for the quarter. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. During the same quarter in the prior year, the company posted $1.72 EPS. The business’s revenue was down 12.3% on a year-over-year basis. On average, analysts expect ICU Medical to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ICU Medical Price Performance

Shares of ICU Medical stock opened at $166.53 on Thursday. The firm has a market cap of $4.16 billion, a P/E ratio of 90.02, a price-to-earnings-growth ratio of 2.32 and a beta of 0.76. The firm’s 50-day simple moving average is $146.57 and its 200-day simple moving average is $140.00. ICU Medical has a twelve month low of $107.00 and a twelve month high of $170.48. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34.

Insider Buying and Selling at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently made changes to their positions in the stock. Corient Private Wealth LLC raised its holdings in shares of ICU Medical by 1,299.9% during the fourth quarter. Corient Private Wealth LLC now owns 56,822 shares of the medical instruments supplier’s stock worth $8,107,000 after acquiring an additional 52,763 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in ICU Medical by 89.9% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,815 shares of the medical instruments supplier’s stock worth $687,000 after purchasing an additional 2,280 shares during the period. EP Wealth Advisors LLC bought a new stake in shares of ICU Medical in the fourth quarter valued at about $634,000. Mackenzie Financial Corp acquired a new position in shares of ICU Medical during the fourth quarter worth about $219,000. Finally, XTX Topco Ltd bought a new position in shares of ICU Medical during the fourth quarter worth about $511,000. Institutional investors own 96.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. BTIG Research started coverage on ICU Medical in a report on Monday, June 15th. They set a “buy” rating and a $170.00 price objective for the company. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Piper Sandler lowered their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $172.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.